Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease

Heart

Volumn 101, Issue 12, 2015, Pages 961-966

  Patel, Vimal ^a   O'Mahony, Constantinos ^a   Hughes, Derralynn ^b   Rahman, Mohammad Shafiqur ^c   Coats, Caroline ^a   Murphy, Elaine ^d   Lachmann, Robin ^d   Mehta, Atul ^b   Elliott, Perry M ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF DHAKA   (Bangladesh)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVERSE OUTCOME; AGE; ARTICLE; ARTIFICIAL HEART PACEMAKER; ATRIAL FIBRILLATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DEVICE THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; FABRY DISEASE; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HEART DEATH; HEART FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; QRS INTERVAL; COMPLICATION; COST OF ILLNESS; DEATH; FORECASTING; GENETICS; HEART DISEASES; MIDDLE AGED; MORTALITY; SEVERITY OF ILLNESS INDEX;

ADULT; AGE FACTORS; ATRIAL FIBRILLATION; BRADYCARDIA; COST OF ILLNESS; DEATH; FABRY DISEASE; FEMALE; FORECASTING; HEART DISEASES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PACEMAKER, ARTIFICIAL; SEVERITY OF ILLNESS INDEX;

EID: 84930226122     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-306782     Document Type: Article

References (27)

1. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008;372:1427-35.
2. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-42.
3. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-93.
4. Eng CM, Resnick-Silverman LA, Niehaus DJ, et al. Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet 1993;53:1186-97.
5. Elliott PM. Anderson-Fabry Disease: an important differential diagnosis in patients with unexplained left ventricular hypertrophy. Heart Metab 2006;33:25-9.
6. von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991;324:395-9.
7. Ishii S, Sakuraba H, Suzuki Y. Point mutations in the upstream region of the alpha-galactosidase A gene exon 6 in an atypical variant of Fabry disease. Hum Genet 1992;89:29-32.
8. Eng CM, Ashley GA, Burgert TS, et al. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 1997;3:174-82.
9. Eng CM, Niehaus DJ, Enriquez AL, et al. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene. Hum Mol Genet 1994;3:1795-9.
10. Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001;345:25-32.
11. Ishii S, Nakao S, Minamikawa-Tachino R, et al. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet 2002;70:994-1002.
12. Beck M. The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease. Acta Paediatr Suppl 2006;95:43-6.
13. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79-108.
14. Teicholz LE, Cohen MV, Sonnenblick EH, et al. Study of left ventricular geometry and function by B-scan ultrasonography in patients with and without asynergy. N Engl J Med 1974;291:1220-6.
15. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th edn. Boston: Mass: Little, Brown & Co, 1994.
16. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-18.
17. Firth D. Bias Reduction of Maximum Likelihood Estimates. Biometrika 1993;80:27-38.
18. Heinze G, Schemper M. A Solution to the Problem of Monotone Likelihood in Cox Regression. Biometrics 2001;57:114-19.
19. Harrell FE Jr. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis, 2010.
20. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007;93:528-35.
21. Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-35.
22. Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006;92:357-60.
23. Moon JC, Sheppard M, Reed E, et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 2006;8:479-82.
24. Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003;24:2151-5.
25. O'Mahony C, Coats C, Cardona M, et al. Incidence and predictors of antibradycardia pacing in patients with Anderson-Fabry disease. Europace 2011;13:1781-8.
26. Germain DP, Poenaru L. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches. Biochem Biophys Res Commun 1999;257:708-13.
27. Rodriguez-Mari A, Coll MJ, Chabas A. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum Mutat 2003;22:258.